# US 2012/0252729 A1 · Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week in a unit dose of 100 to 200 units

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252729 A1
- Document ID: US20120252729A1
- Status: Published application
- Kind: A1
- Application number: 13/395,000
- Filed: 2010-09-08
- Published: 2012-10-04
- Earliest claimed: 2009-09-09
- Assignees: Asahi Kasei Pharma Corporation
- Inventors: Shinichiro Shirae; Yasuo Nakamura; Yuiko Oya; Yoshihide Nozaki; Nobuyuki Kobayashi; Tatsuhiko Kuroda; Hiroki Kato; Masashi Serada; Kazuyoshi Hori
- Web page: https://patentgrep.com/patent/US20120252729A1

## CPC

- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61K 33/10: Carbonates; Bicarbonates
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/18: of the parathyroid hormones
- A61P 9/12: Antihypertensives
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating osteoporosis by PTH that has excellent safety and high efficacy is disclosed, along with a method for inhibiting/preventing bone fractures by PTH that has excellent safety, as well as providing a drug to do this. A drug containing PTH as the active ingredient is disclosed, characterized in that a unit dose of PTH of 100 to 200 units is administered weekly in the above method.

## Claims

### Claim 1

An agent for the treatment or prevention of osteoporosis that contains PTH as the active ingredient, characterized in that it is used in conjunction with a calcium agent and PTH is administered once a week in a unit dose of 100 to 200 units.

### Claim 2 (depends on 1)

An agent for the treatment or prevention of osteoporosis of claim 1, characterized in that the calcium agent used in combination is administered one or more times a week.

### Claim 3 (depends on 1)

An agent for the treatment or prevention of osteoporosis of claims 1, characterized in that the calcium agent used in combination is administered in a dose of 200 to 800 mg/day as calcium.

### Claim 4 (depends on 1)

An agent for the treatment or prevention of osteoporosis of claim 1, wherein the above PTH is human PTH (1-34).

### Claim 5 (depends on 1)

An agent for the treatment or prevention of osteoporosis of claim 1 to be administered over a duration exceeding 24 weeks or 48 weeks.

### Claim 6 (depends on 1)

An agent for the treatment or prevention of osteoporosis of claim 1 to treat osteoporosis patients who satisfy all of the following conditions (1) through (3) below:
(1) Age 65 years or older
(2) Prevalent bone fractures
(3) Bone density less than 80% of the young adult mean and/or degree of bone atrophy of I or higher.

### Claim 7 (depends on 1)

An agent for the treatment or prevention of osteoporosis of claim 1 to treat or prevent secondary osteoporosis caused by glucocorticoid or diabetic osteoporosis.

### Claim 8 (depends on 1)

An agent for the treatment or prevention of osteoporosis of claim 1 to treat or prevent osteoporosis having at least one of the diseases of (1) through (8) below as a complication:
(1) Diabetes,
(2) Hypertension,
(3) Hyperlipidemia,
(4) Arthralgia,
(5) Osteoarthritis of the spine,
(6) Metatypical low back pain,
(7) Osteoarthritis of the hip,
(8) Osteoarthritis of the jaw.

### Claim 9 (depends on 1)

An agent for the treatment or prevention of osteoporosis of claim 1 to be administered to an osteoporosis patient having a history of being administered at least one of the osteoporosis therapeutic agents of (1) through (6) below:
(1) Calcium L-aspartate
(2) Alfacalcidol,
(3) Elcatonin,
(4) Raloxifene hydrochloride,
(5) Menatetrenone,
(6) Calcium lactate

### Claim 10 (depends on 1)

An agent for the treatment or prevention of osteoporosis of claim 1 to be administered to osteoporosis patients having mild renal dysfunction or moderate renal dysfunction.

### Claim 11 (depends on 6)

An agent for the treatment or prevention of osteoporosis of claim 6 wherein the above PTH is human PTH (1-34).

### Claim 12 (depends on 6)

An agent for the treatment or prevention of osteoporosis of claim 6 wherein the above osteoporosis therapeutic agent containing PTH as the active ingredient is a subcutaneous injection.

### Claim 13 (depends on 1)

A combination preparation or treatment kit consisting of an agent for the treatment or prevention of osteoporosis listed in claim 1 and at least one drug of (1)-(6) below.
(1) Metoclopramide,
(2) Domperidone,
(3) Famotidine,
(4) Mosapride citrate,
(5) Lansoprazole,
(6) Rokushingan.

### Claim 14

An agent for the treatment or prevention of osteoporosis that contains PTH as the active ingredient, characterized in that PTH is administered once a week in a unit dose of 100 to 200 units, the agent for the treatment or prevention of osteoporosis being used to treat osteoporosis patients who satisfy all of the following conditions (1) through (3):
(1) Age 65 years or older
(2) Prevalent bone fractures
(3) Bone density less than 80% of the young adult mean and/or degree of bone atrophy of I or higher.

### Claim 15

An agent for the treatment or prevention of osteoporosis at high risk for bone fractures that contains PTH as the active ingredient, characterized in that PTH is administered once a week in a unit dose of 100 to 200 units.

### Claim 16

An agent for the treatment or prevention of osteoporosis that contains PTH as the active ingredient, characterized in that PTH is administered once a week in a unit dose of 100 to 200 units, the agent for the treatment or prevention of osteoporosis being used to treat or prevent secondary osteoporosis caused by glucocorticoid or diabetic osteoporosis.

### Claim 17

An agent for the treatment or prevention of osteoporosis that contains PTH as the active ingredient, characterized in that PTH is administered once a week in a unit dose of 100 to 200 units, the agent for the treatment or prevention of osteoporosis being administered to osteoporosis patients having mild renal dysfunction or moderate renal dysfunction.

### Claim 18

An agent for the inhibition or prevention of bone fractures that contains PTH as the active ingredient, characterized in being used in conjunction with a calcium agent and PTH is administered once a week in a unit dose of 100 to 200 units.

### Claim 19 (depends on 18)

An agent for the inhibition or prevention of bone fractures of claim 18, characterized in that the calcium agent used in combination is administered one or more times a week.

### Claim 20 (depends on 18)

An agent for the inhibition or prevention of bone fractures of claims 18, characterized in that the calcium agent used in combination is administered in a dose of 200 to 800 mg/day as calcium.

### Claim 21 (depends on 18)

An agent for the inhibition or prevention of bone fractures of claim 18, wherein the above PTH is human PTH (1-34).

### Claim 22 (depends on 18)

An agent for the inhibition or prevention of bone fractures of claim 18 to be administered to subjects who fulfill all of the following conditions (1) through (3):
(1) Age 65 years or older
(2) Prevalent bone fractures
(3) Bone density less than 80% of the young adult mean and/or degree of bone atrophy of I or higher.

### Claim 23 (depends on 22)

An agent for the inhibition or prevention of bone fractures of claim 22 wherein the above PTH is human PTH (1-34).

### Claim 24 (depends on 22)

An agent for the inhibition or prevention of bone fractures of claims 22, wherein the above agent for the inhibition or prevention of bone fractures that contains PTH as the active ingredient is a subcutaneous injection.

### Claim 25 (depends on 18)

An agent for the inhibition or prevention of bone fractures of claim 18, wherein the agent for the inhibition or prevention of bone fractures is an agent for the inhibition of multiple bone fractures or the prevention of multiple bone fractures.

### Claim 26 (depends on 18)

An agent for the inhibition or prevention of bone fractures of claim 18, wherein the agent for the inhibition or prevention of bone fractures is an agent for the inhibition of worsening fractures or the prevention of worsening fractures.
